Compare TG & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | OABI |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.2M | 277.8M |
| IPO Year | 1989 | N/A |
| Metric | TG | OABI |
|---|---|---|
| Price | $8.70 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 164.8K | ★ 320.4K |
| Earning Date | 03-11-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $691,173,000.00 | $21,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.20 |
| P/E Ratio | $133.18 | ★ N/A |
| Revenue Growth | ★ 43.30 | 3.36 |
| 52 Week Low | $6.25 | $1.22 |
| 52 Week High | $9.43 | $4.02 |
| Indicator | TG | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 67.70 | 52.79 |
| Support Level | $8.38 | $1.85 |
| Resistance Level | $8.98 | $2.10 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 82.02 | 44.23 |
Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.